Medical/Pharmaceuticals
Singleron to present single cell sequencing solutions at the 36th Molecular Biology of Plants Conference
COLOGNE, Germany, Jan. 31, 2023 /PRNewswire/ -- Singleron Biotechnologies
2023-01-31 16:00
3132
Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autolog...
2023-01-31 09:24
3142
Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China
BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in p...
2023-01-30 23:00
3141
Health in Tech to Attend Health Care Administration Association (HCAA) Executive Forum 2023 as Corporate Sponsor
HCAA's Executive Forum 2023 is scheduled for February 20-22, 2023, at the Bellagio inLas Vegas. Be sure to stop by booth NL #9 to meet Health in Tech leadership. STUART, Fla., Jan. 30, 2023 /PRNewswire/ -- Health in Tech ("HIT", or "the Company"), an industry-leading Insurtech company that deliv...
2023-01-30 22:00
2254
Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases
SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially ...
2023-01-30 10:00
2827
SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs
* SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in theKingdom of Saudi Arabia(KSA) * SK bioscience also explained a new global partnership model aiming to promote public health in deve...
2023-01-27 20:00
5169
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...
2023-01-27 14:52
4692
Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab
HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced the Hart-Scott-Rodino (HSR) Act filing has c...
2023-01-26 20:24
4627
SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane
* First Generic of Abraxane in Korea, World 4th Commercial Scale-Up * Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea ,Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEOJang Doo-hyun) signed a domestic manufacturing technology transf...
2023-01-26 14:31
3176
ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies
NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative medicine industry has shown tremendous potential in clinical practices in recent years worldwide,China's blue ocean market welcomes the first wave of acquisitions. ReLive Biotechnologies, Ltd. ("ReLive" or "...
2023-01-26 12:11
2794
iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax
* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack * Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit * Further developments are planned to conduct with a licensing/col...
2023-01-26 10:34
2694
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated byHarbour BioMed (HKEX: 02142), announced that it completed seed financing to advance its leading programs, novel antibody therapies to treat congenital adrenal hype...
2023-01-26 09:22
3904
ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies
NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative treatment industry has shown tremendous potential in clinical practices in recent years worldwide,China's blue ocean market welcomes the first wave of acquisitions. ReLive Biotechnologies, Ltd. ("ReLive" or ...
2023-01-26 08:11
3066
Singleron launches single cell eQTL analysis as part of their sequencing service
A new bioinformatic pipeline to investigate single cell eQTL analysis is now
offered in the sequencing service from Singleron Biotechnologies.
COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at
Singleron Biotechnologies
2023-01-25 19:00
2684
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK, Jan. 20, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company mush complete its initial business combination fromJanuary 19, 2023 to February 19, 2023, for each public share that...
2023-01-21 05:33
7145
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thata poster presentation highlighting the Phase 1 preliminary result...
2023-01-20 21:50
5526
International Symposium at the Vatican on Hansen's Disease To Focus on Theme of "Leave No One Behind"
TOKYO, Jan. 20, 2023 /PRNewswire/ -- French Raoul Follereau Fondation, Italian Association Amici di Raoul Follereau and Sasakawa Leprosy (Hansen's Disease) Initiative, in collaboration with the Dicastery for Promoting Integral Human Development, will co-host the "International Symposium at the Va...
2023-01-20 21:00
4746
SK bioscience Appoints New Executives to Accelerate New Growth Strategies
* Two biopharmaceutical experts join SK bioscience to strengthen the future strategies * With recruitment of global talent and capabilities accumulated during the COVID-19 pandemic, SK bioscience will continue to achieve sustainable growth SEOUL, South Korea, Jan. 20, 2023 /PRNewswire/ -- SK ...
2023-01-20 20:00
4073
DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced that the U.S. Food...
2023-01-20 18:00
4201
BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS
TORONTO, Canada and BEIJING, Jan. 20, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at theAmerican Association for Cancer Research (AACR) <...
2023-01-20 13:10
2884
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS
2026-10-04 00:56
10671
Nuix Neo Generative AI Framework
2026-10-08 08:02
9102
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8125
